Monoclonal antibody (mAb) development continues to evolve – with increasingly complex formats demanding more sophisticated purification methods, especially during the polishing stage. Challenges such ...

As monoclonal antibody (mAb) development continues to evolve, new challenges are arising in the purification process, especially during the polishing stage. Innovations in flow-through technology – ...

Vendors Bank on the Prospect of Successful End-to-End Continuous Manufacturing for Biologics Continuous processing has been a mainstay in process industries for decades, but is conspicuously rare in ...

Next-generation manufacturing of monoclonal antibodies (mAbs) will rely on continuous processes featuring single-use adsorbents, small-footprint production, and minimal aqueous buffer volumes, ...

Upstream titers of 3–5 g/L, and up to 10–13 g/L, are outpacing downstream capacity, creating chromatography, filtration, and UF/DF throughput bottlenecks that elevate cost and delay timelines. Complex ...

Although biopharmaceutical manufacturing covers an extensive range, it is essential that each iteration of a unit operation is in compliance with an unyielding set of operational parameters and ...